IBEX Grant of Options
(firmenpresse) - MONTREAL, QUEBEC -- (Marketwired) -- 07/03/13 -- IBEX Technologies Inc. (TSX VENTURE: IBT) today announces the grant of options to Richard Collin, CPA, CA, its newly appointed Director of Finance.
In connection with his appointment, Mr. Collin has been granted options to acquire up to 50,000 common shares of IBEX at an exercise price of $0.08 per common share for a term of 10 years pursuant to IBEX's incentive stock option plan.
ABOUT IBEX
The Company, through its wholly owned subsidiaries, IBEX Pharmaceuticals Inc. (Montreal, QC) and Bio-Research Products Inc. (North Liberty, IA), manufactures and markets enzymes for biomedical use. IBEX also manufactures and markets a series of arthritis assays which are widely used in osteoarthritis research.
For more information, please visit the Company's website at .
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
IBEX Technologies Inc.
Paul Baehr
President & CEO
514-344-4004 x 143
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 03.07.2013 - 12:50 Uhr
Sprache: Deutsch
News-ID 1242587
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
MONTREAL, QUEBEC
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 131 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"IBEX Grant of Options
"
steht unter der journalistisch-redaktionellen Verantwortung von
IBEX Technologies Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
